James Mccollum Buys Shares of LENZ
James Mccollum acquired 22,100 shares of LENZ on June 15, 2026.
Key Points
- James Mccollum bought 22,100 shares of LENZ on June 15, 2026, as part of an insider buying activity.
- Shares of LENZ traded at $6.77, with several institutional investors adjusting their positions recently.
- Analysts have mixed ratings on LENZ, with Citigroup maintaining a 'buy' and Piper Sandler downgrading to 'hold'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
James Mccollum, an insider at LENZ, purchased 22,100 shares of the company on June 15, 2026. This transaction is part of recent insider buying activity.
Other Institutional Activity in LENZ
Several institutional investors have also been active in LENZ recently. Versant Venture Management, LLC doubled its holdings by adding 2,656,888 shares, ending with 5,313,776 shares valued at approximately $48.6 million. BlackRock, Inc. increased its stake by 284,817 shares, bringing its total to 1,976,823 shares worth about $18.1 million. Meanwhile, FMR LLC trimmed its position by 104,934 shares, resulting in 3,597,784 shares valued at around $32.9 million.
LENZ Therapeutics, Inc. Stock Up 32.5%
Shares of LENZ are currently trading at $6.77. The stock has seen various institutional adjustments, reflecting ongoing market interest.
Insider Buying and Selling at LENZ Therapeutics, Inc.
On June 15, 2026, multiple insiders, including James Mccollum, Zachary Scheiner, and Frederic Guerard, each purchased 22,100 shares of LENZ. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On May 13, 2026, Citigroup maintained its 'buy' rating on LENZ with a price target of $20. HC Wainwright & Co. also maintained a 'buy' rating, setting a target of $38 on May 12, 2026. However, Piper Sandler downgraded the stock to 'hold' with a $12 target on the same day. Market analysts show a mix of optimism and caution regarding LENZ's future prospects.
Bottom Line
James Mccollum's purchase of LENZ shares is a noteworthy insider activity, highlighting confidence in the company. Institutional investors have also been actively adjusting their positions, indicating varied market sentiment. Analysts provide mixed ratings, reflecting differing views on LENZ's potential, with some maintaining a positive outlook while others exercise caution.
Get LENZ Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LENZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.